TrialCancer science2017

Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.

Kenji Tamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.